<DOC>
	<DOCNO>NCT01310127</DOCNO>
	<brief_summary>This single-center , randomize , investigator-masked , parallel group , active-comparator control study investigate clinical outcome visual acuity macular thickness treatment Bromday ( bromfenac ophthalmic solution ) 0.09 % QD Nevanac ( nepafenac ophthalmic suspension ) 0.1 % TID subject undergone cataract extraction posterior chamber intraocular lens implantation .</brief_summary>
	<brief_title>Clinical Outcomes Bromday ( Bromfenac Ophthalmic Solution ) 0.09 % QD vs. Nevanac ( Nepafenac Ophthalmic Suspension ) 0.1 %</brief_title>
	<detailed_description>Two topical NSAIDs currently approve postoperative treatment pain inflammation cataract surgery bromfenac 0.09 % nepafenac 0.1 % . Both purport treat ocular inflammation act potent inhibitor COX-1 COX-2 enzyme . Clinical study date lack clarity topical NSAID may efficacious .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pseudophakia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Are male female least 18 year age schedule unilateral cataract surgery ( phacoemulsification extracapsular ) posterior chamber intraocular lens implantation ophthalmic surgical procedure ( e.g. , relax incision , iridectomy , conjunctival excision , etc ) conduct cataract surgery . Agree ocular surgical procedure study fellow ( non study ) eye within 15 day prior initiation dose test article throughout duration study . Have Best Corrected Visual Acuity 20/200 good either eye . If woman capable become pregnant , agree urine pregnancy test perform screening ( must negative ) agree use medically acceptable form birth control throughout study duration least one week prior completion study . Women consider capable become pregnant include female experience menarche experience menopause ( define amenorrhea great 12 consecutive month ) undergo successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) . Have IOP ≥ 5 mmHg ≤ 22 mmHg ( study eye ) without anti glaucoma therapy pre operative screening visit ( &gt; 22 mmHg , adjust follow pachymetry ) . Have know hypersensitivity bromfenac Nepafenac component test article ( include `` procedural '' medication anesthetic and/or fluorescein drop , dilate drop , etc. ) . Have know hypersensitivity salicylate ( i.e. , aspirin ) non steroidal anti inflammatory drug ( NSAIDs ) . Have intraocular inflammation ( i.e. , cell flare anterior chamber measure slit lamp examination ) study eye screen visit . Have know blood dyscrasia bone marrow suppression , diagnosis uncontrolled/unstable peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , uncontrolled/unstable pulmonary , cardiac , vascular , autoimmune , hepatic , renal , central nervous system disease . Have use ocular , topical , systemic NSAIDs ocular , topical , systemic gentamicin , cyclosporine ophthalmic emulsion within 7 day prior initiation dose test article throughout duration study . Have use ocular prostaglandin within 30 day prior initiation dose test article throughout duration study . Have active corneal pathology note study eye screen visit . Active corneal pathology define corneal pathology non stable , great mild , compromise assessment safety efficacy treatment . Superficial punctate keratitis study eye criterion exclusion . Have use topical , ocular , inhaled systemic steroid within 14 day prior screen . Have radial keratotomy , corneal transplant , corneal refractive surgery study eye within last two year . Are pregnant nursing/lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>NSAID</keyword>
	<keyword>Ocular Inflammation</keyword>
	<keyword>bromfenac</keyword>
</DOC>